Compare Quest Diagnostics Inc (DGX) vs Synchrony Financial (SYF) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs Synchrony Financial — how do they compare? Quest Diagnostics Inc trades at $205.45 (market cap $22.80B), while Synchrony Financial trades at $73.68 (market cap $24.78B). The key difference: Quest Diagnostics Inc and Synchrony Financial are close in size by market cap, and Quest Diagnostics Inc pays the higher dividend (1.67%). Which is the better fit depends on your goals.
| DGX | SYF | |
|---|---|---|
Market Cap | $22.80B | $24.78B |
Sector | Health | Financials |
52-Week High | $216.02 | $88.47 |
52-Week Low | $166.42 | $63.78 |
Enterprise Value | $28.82B | — |
Dividend Yield | 1.67% | 1.63% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $207.35, showing minimal daily movement with a slight decline of 0.04%. The stock maintains a bullish technical stance with recent earnings beats and analyst consensus pointing to upside potential. Recent developments include New York State approval for Haystack MRD testing and strong momentum across diagnostic channels. Revenue growth accelerated to $11.04 billion in 2025 with consistent profitability margins around 9%.
DGX presents a balanced investment case with 38% analyst buy ratings and a $227.75 price target suggesting 10% upside. The company demonstrates steady revenue growth and operational efficiency, though elevated debt levels and policy risks require monitoring. Second quarter earnings on July 23, 2026, will be crucial for validating current momentum and growth trajectory.
SYF trades at $73.21, up 1.06% today, with a bearish technical signal but strong fundamentals. The stock shows a low P/E of 7.63 and robust profitability with a 24.06% net income margin. Recent earnings beats and a $0.30 dividend highlight operational strength, while analyst consensus is bullish with a $86.38 price target.
Outlook remains positive due to earnings momentum and undervaluation, but risks include economic sensitivity and technical weakness. The stock offers value with upside potential, though investors should monitor loan performance and interest rate impacts on financial results.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About Synchrony Financial
Synchrony Financial is a premier consumer financial services company and the largest provider of private-label credit cards in the United States. Spun off from GE Capital in 2014, it operates through a unique B2B2C model, embedding its financing products within the ecosystems of major partners like Amazon, Lowe’s, and PayPal. Synchrony leverages deep data analytics and a diverse multi-platform strategy—spanning retail, health, and auto—to drive customer loyalty and provide specialized credit solutions at the point of sale.
Read more on SYF →
